Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp RVXCF


Primary Symbol: T.RVX

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp > Interference
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(13)
•••
Comment by narmacon Jan 18, 2022 11:32am
212 Views
Post# 34328681

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Interference

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:InterferenceOttawa is busy attepting to negotiate oral pills from Merck and Pfizer!!,, JT will blow his load with BP. Probably little to nothing will be left for a lethargic no namer like RVX. Especially with our track record!!,,,,working around RVX is looked at like being in a sewer. Pinocchio will have 50 patients across the globe to show efficacy in this 2b, Talk about over powered,,,woooooow!!!!!,,,nothing short of wishful thinking by this group of management misfits!,,, I dont expect a successful trial due to the inability of this team to understand and design same. This has been proven time and time again by RVX. And I dont believe one forward statement made by this CEO!

..52 end of day is my prediction,,maybe lower.

Best of luck to all us bag holders!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities